Skip to Content

Ibrexafungerp FDA Approval Status

FDA Approved: No
Generic name: ibrexafungerp
Company: Scynexis, Inc.
Treatment for: Vaginal Yeast Infection

Ibrexafungerp is a first-in-class triterpenoid antifungal agent in development for the treatment of vulvovaginal candidiasis.

Development Timeline for ibrexafungerp

DateArticle
Oct 14, 2020Scynexis Announces Submission of New Drug Application to the U.S. Food and Drug Administration for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infection
Jan 30, 2019Scynexis Announces Positive Interim Results from Phase 3 Open-Label FURI Study, Showing Oral Ibrexafungerp's Ability to Treat Refractory Fungal Infections and to Provide an Alternative to Long-Term IV Therapies

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.